Navigation Links
Cancer research presented at 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium
Date:12/1/2010

SAN ANTONIO More than 9,000 people from more than 90 countries will gather Dec. 8-12, 2010, at the Henry B. Gonzales Convention Center in San Antonio, Texas, for the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.

The symposium is the largest of its kind anywhere in the world. Each year it draws academicians, clinicians, survivors, patient advocates, industry and others interested in the advancement of breast cancer research to discuss and learn about new and late-breaking research, which includes experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and pre-malignant breast disease, as well as new findings from clinical trials.

The CTRC-AACR San Antonio Breast Cancer Symposium is a partnership between the Cancer Therapy and Research Center (CTRC) at UT Health Science Center San Antonio, the American Association for Cancer Research and Baylor College of Medicine.

"The driving force behind this collaboration is the shared mission of the organizations to advance progress against breast cancer," said Program Chairperson C. Kent Osborne, M.D., director of the Dan L. Duncan Cancer Center at the Baylor College of Medicine. "By combining their respective strengths, the San Antonio Breast Cancer Symposium encompasses the full spectrum of breast cancer research and facilitates the rapid transition of new knowledge into improved care for breast cancer patients."

The symposium begins on Wednesday, Dec. 8, with a full schedule of educational events. The opening plenary session begins the next day at 8:30 a.m. CT in Exhibit Hall D of the Henry B. Gonzales Convention Center.

In addition to the ongoing plenary session, there is a full industry exhibit hall and a program for survivors and breast cancer advocates. Press conferences will be held for registered members of the media.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1

Related medicine news :

1. FDA Panel to Vote on Drugs Said to Prevent Prostate Cancer
2. Finger length points to prostate cancer risk
3. FDA Panel to Vote on Drugs to Prevent Prostate Cancer
4. Cancer risk from medical radiation may have been overestimated
5. Annual breast cancer screening beginning at age 40 reduces mastectomy risk
6. Active surveillance for low-risk prostate cancer may offer better quality-of-life
7. Breast Cancer Rates Lower With Less Hormone Therapy: Study
8. Study Backs Active Surveillance for Low-Risk Prostate Cancer
9. Celebrex may help prevent some non-melanoma skin cancers
10. Experimental vaccine sets sights on lung cancer
11. Drop in breast cancer rates directly tied to reduced hormone therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... 18, 2017 , ... Mediaplanet today announces the launch of ... and highlighting the importance of proactive eye and ear health. The campaign focuses ... innovations in hearing aid technology. , In this issue, the American Speech-Language-Hearing ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Dawn Johnson Insurance Group, ... new charity drive to generate community support for efforts to educate the local population ... treatments for all types of cancer. , Each day in America, roughly 4,600 ...
(Date:8/18/2017)... ... August 18, 2017 , ... Radabaugh & ... assistance to communities in North-Central West Virginia, is embarking on a cooperative charity ... in the area. , The Chestnut Mountain Ranch (CMR) is a Christ-centered boarding ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... planning assistance that serves communities throughout southern Florida, is working to support the ... assets to children from low income families. , The Take Stock In Children ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... and financial planning firm that serves residential and commercial clients in the greater ... drive to raise community support for the fight against cancer. , Founded by ...
Breaking Medicine News(10 mins):
(Date:8/14/2017)... HACKENSACK, N.J. and PETACH TIKVAH, ... Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ... for the second quarter ending June 30, 2017. ... advanced stages of preparing for our pivotal Phase 3 ... Chaim Lebovits , President and Chief Executive Officer ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... , Aug. 7, 2017 Zimmer Biomet Holdings, Inc. ... today announced that its Board of Directors has approved the ... third quarter of 2017. ... on or about October 27, 2017 to stockholders of record ... Future declarations of dividends are subject to approval of the ...
Breaking Medicine Technology: